Magnesium sulfate 50% (magnesium 2mmol/ml) solution for injection 10ml ampoules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium sulfate 50% (magnesium 2mmol/ml) solution for injection 10ml ampoules

magnesium 2mmol/ml) solution for injection 10ml ampoules (martindale pharmaceuticals ltd - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

PRISMASOL BGK0/2.5- calcium chloride, magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride and sodium bicarbonate injection PRISMASOL BGK4/2.5- calcium chloride, magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection PRISMASOL BGK2/3.5- calcium chloride, magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection PRISMASOL BGK2/0- magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection PRISMASOL B22GK4/0- magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection PRISMASOL BK0/0/1.2- magnesium chloride, lactic acid, sodium chloride and sodium bicarbonate injection PRISMASOL BGK4/0/1.2- magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection PHOXILLUM BK4/2.5- calcium chloride, magnesium chloride, sodium chloride, sodium bicarbonate, potassium chloride and sodium phosphate dibasic dihydrate injection PHOXILLUM B22K4/0- magnesium chloride, sodium chloride, sodium bicarbonate, potassium chloride and sodium phosphate dibasic dihydrate injection United States - English - NLM (National Library of Medicine)

prismasol bgk0/2.5- calcium chloride, magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride and sodium bicarbonate injection prismasol bgk4/2.5- calcium chloride, magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection prismasol bgk2/3.5- calcium chloride, magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection prismasol bgk2/0- magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection prismasol b22gk4/0- magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection prismasol bk0/0/1.2- magnesium chloride, lactic acid, sodium chloride and sodium bicarbonate injection prismasol bgk4/0/1.2- magnesium chloride, dextrose monohydrate, lactic acid, sodium chloride, sodium bicarbonate and potassium chloride injection phoxillum bk4/2.5- calcium chloride, magnesium chloride, sodium chloride, sodium bicarbonate, potassium chloride and sodium phosphate dibasic dihydrate injection phoxillum b22k4/0- magnesium chloride, sodium chloride, sodium bicarbonate, potassium chloride and sodium phosphate dibasic dihydrate injection

baxter healthcare corporation - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), lactic acid, unspecified form (unii: 33x04xa5at) (lactic acid, unspecified form - unii:33x04xa5at), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20) - calcium chloride 0.184 g in 1 l - prismasol and phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in continuous renal replacement therapy (crrt) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. they may also be used in case of drug poisoning when crrt is used to remove dialyzable substances. phoxillum and prismasol replacement solutions are contraindicated in patients with known hypersensitivities to these products. prismasol and phoxillum are pharmacologically inactive solutions. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. animal reproduction studies have not been conducted with prismasol and phoxillum solutions. the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. maintenance of normal acid-base balance is important for fetal well-being. the components of prismasol and phoxillum solutions are excreted in human milk. appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant. safety and effectiveness have been established based on published clinical data of crrt replacement solutions with compositions similar to prismasol and phoxillum used in adults and two hemofiltration studies in pediatric patients, including a study of newborns to 17 years old. the experience with prismasol and phoxillum solutions in geriatric patients has not identified novel concerns.

Rennie Deflatine Chewable Tablets Calcium Carbonate 680mg Magnesium Carbonate 80mg Simeticone 25mg Ireland - English - HPRA (Health Products Regulatory Authority)

rennie deflatine chewable tablets calcium carbonate 680mg magnesium carbonate 80mg simeticone 25mg

bayer limited - calcium carbonate; magnesium carbonate; simeticone - chewable tablet - 680 mg/80 mg/25 milligram(s) - magnesium carbonate; calcium carbonate; antacids, other combinations; silicones

MAGNESIUM SULFATE 50 % WV INOVAMED Israel - English - Ministry of Health

magnesium sulfate 50 % wv inovamed

inovamed ltd - magnesium sulfate as heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate as heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate 50%w/v inovamed is indicated for:1. the treatment of magnesium deficiency in hypomagnesaemia. 2. the prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutrition. 3. the control and prevention of seizures in severe pre-eclampsia. 4. the control and prevention of recurrent seizures in eclampsia

MAGNESIUM SULFATE KALCEKS 50 % Israel - English - Ministry of Health

magnesium sulfate kalceks 50 %

a.l. medi-market ltd. - magnesium sulfate heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate kalceks 50% solution for injection or infusion is indicated for: the treatment of magnesium deficiency in hypomagnesaemiathe prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutritionthe control and prevention of seizures in severe pre-eclampsiathe control and prevention of recurrent seizures in eclampsia

ACTONEL EC COMBI risedronate sodium 35mg enteric-coated tablet and calcium carbonate 1250mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

actonel ec combi risedronate sodium 35mg enteric-coated tablet and calcium carbonate 1250mg tablet blister pack

theramex australia pty ltd - calcium carbonate,risedronate sodium -

ACTONEL EC COMBI D risedronate sodium 35mg enteric-coated tablet / calcium carbonate 2500 mg and colecalciferol 22 microgram gra Australia - English - Department of Health (Therapeutic Goods Administration)

actonel ec combi d risedronate sodium 35mg enteric-coated tablet / calcium carbonate 2500 mg and colecalciferol 22 microgram gra

theramex australia pty ltd - calcium carbonate,colecalciferol,risedronate sodium -

Bisodol Antacid Chewable TabletsCalcium Carbonate 522mgMagnesium Carbonate Light 68mgSodium Hydrogen Carbonate 64mg Ireland - English - HPRA (Health Products Regulatory Authority)

bisodol antacid chewable tabletscalcium carbonate 522mgmagnesium carbonate light 68mgsodium hydrogen carbonate 64mg

teva b.v. - calcium carbonate; sodium hydrogen carbonate; light magnesium carbonate - chewable tablet - 522/68/64 milligram(s) - calcium compounds; calcium carbonate

ALENDRONATE PLUS D3 CAL alendronic acid (as sodium) 70 mg and colecalciferol 140 microgram tablet and calcium 500 mg tablet comp Australia - English - Department of Health (Therapeutic Goods Administration)

alendronate plus d3 cal alendronic acid (as sodium) 70 mg and colecalciferol 140 microgram tablet and calcium 500 mg tablet comp

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

ZOLEDRONIC ACID injection, solution United States - English - NLM (National Library of Medicine)

zoledronic acid injection, solution

mylan institutional llc - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 5 mg in 100 ml - zoledronic acid injection is indicated for treatment of paget's disease of bone in men and women. treatment is indicated in patients with paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see clinical studies (14.5)] . zoledronic acid is contraindicated in patients with the following conditions: in female rats given daily subcutaneous doses of 0.01, 0.03, or 0.1 mg/kg, beginning 15 days before mating and continuing through gestation, parturition and lactation, dystocia and periparturient mortality were observed in pregnant rats allowed to deliver starting at 0.01 mg/kg/day (0.1 times the human 5 mg intravenous dose, based on auc). also, there was an increase in stillbirths and a decrease in neonate survival starting at 0.03 mg/kg/day (0.3 times the human 5 mg dose), while the number of viable newborns and pup body weig